Related Experiment Video

Updated: May 25, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications

Mark P Chao1, Irving L Weissman, Ravindra Majeti

  • 1Institute for Stem Cell Biology and Regenerative Medicine and Cancer Institute, Stanford, CA 94305, USA. mpchao@stanford.edu

Current Opinion in Immunology
|February 8, 2012
PubMed

Insights

Cancer cells evade immune detection by inhibiting phagocytosis, a key clearance process. Targeting the CD47-signal-regulatory protein-α pathway offers a promising strategy for enhancing cancer immunotherapies.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • The immune system is crucial for preventing and controlling cancer growth.
  • Cancers develop mechanisms to evade immune surveillance.
  • Macrophages and other phagocytic cells regulate tumor growth via phagocytosis.

Purpose of the Study:

  • To review the role of tumor immune evasion through phagocytosis inhibition.
  • To focus on the CD47-signal-regulatory protein-α pathway.
  • To discuss the therapeutic potential of targeting this pathway in cancer immunotherapy.

Main Methods:

  • Literature review of immunological and cancer research.
  • Analysis of mechanisms of tumor immune evasion.
  • Exploration of the CD47-SIRPα pathway's role in phagocytosis.

Main Results:

  • Tumor cells frequently inhibit phagocytosis to evade immune clearance.
  • The CD47-signal-regulatory protein-α (SIRPα) axis is a major pathway for this inhibition.
  • Blocking CD47-SIRPα interactions can restore phagocytic activity.

Conclusions:

  • Inhibition of phagocytosis is a critical immune evasion strategy for tumors.
  • The CD47-SIRPα pathway is a key target for overcoming this evasion.
  • Targeting this pathway holds significant potential for improving cancer immunotherapies.

More Related Videos

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization08:13

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

Published on: December 3, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.